Halozyme Therapeutics Inc. (NASDAQ: HALO) is 2.30% higher on its value in year-to-date trading and has touched a low of $29.85 and a high of $45.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HALO stock was last observed hovering at around $38.02 in the last trading session, with the day’s loss setting it -0.21%.
Currently trading at $37.81, the stock is -5.21% and -3.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.79 million and changing -0.55% at the moment leaves the stock -2.49% off its SMA200. HALO registered 5.88% gain for a year compared to 6-month gain of 0.67%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -7.35% loss in the last 1 month and extending the period to 3 months gives it a 8.25%, and is -3.84% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.96% over the week and 2.49% over the month.
Halozyme Therapeutics Inc. (HALO) has around 373 employees, a market worth around $4.80B and $829.25M in sales. Current P/E ratio is 17.93 and Fwd P/E is 8.52. Profit margin for the company is 33.96%. Distance from 52-week low is 26.67% and -15.98% from its 52-week high. The company has generated returns on investments over the last 12 months (17.79%).
The EPS is expected to grow by 27.75% this year
The shares outstanding are 126.77M, and float is at 125.67M with Short Float at 6.28%.
Halozyme Therapeutics Inc. (HALO) Insider Activity
The most recent transaction is an insider sale by LaBarre Michael J., the company’s SVP, CHIEF TECHNICAL OFFICER. SEC filings show that LaBarre Michael J. sold 10,000 shares of the company’s common stock on Apr 17 ’24 at a price of $38.49 per share for a total of $0.38 million. Following the sale, the insider now owns 0.17 million shares.
Halozyme Therapeutics Inc. disclosed in a document filed with the SEC on Apr 16 ’24 that LaBarre Michael J. (SVP, CHIEF TECHNICAL OFFICER) sold a total of 10,000 shares of the company’s common stock. The trade occurred on Apr 16 ’24 and was made at $38.35 per share for $0.38 million. Following the transaction, the insider now directly holds 0.17 million shares of the HALO stock.
Still, SEC filings show that on Mar 13 ’24, LaBarre Michael J. (SVP, CHIEF TECHNICAL OFFICER) disposed off 10,000 shares at an average price of $42.27 for $0.42 million. The insider now directly holds 156,558 shares of Halozyme Therapeutics Inc. (HALO).
